MAXIPIME (cefepime hydrochloride) by Pfizer is [ see microbiology ( ]. Approved for the treatment of pneumonia (moderate to severe) caused by susceptible strains of streptococcus pneumoniae, including cases associated with concurrent bacteremia, pseudomonas aeruginosa and 15 more indications. First approved in 1996.
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
MAXIPIME (cefepime hydrochloride) is a fourth-generation cephalosporin antibiotic administered by injection for moderate-to-severe bacterial infections. It treats pneumonia, urinary tract infections, skin infections, and intra-abdominal infections caused by susceptible gram-positive and gram-negative organisms. The drug works by inhibiting bacterial cell wall synthesis, a mechanism typical of beta-lactam antibiotics.
Product approaching loss of exclusivity with limited remaining market opportunity; career growth constrained by mature lifecycle stage and generic erosion.
[ See Microbiology ( ].
Worked on MAXIPIME at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on MAXIPIME offers limited career growth due to approaching loss of exclusivity and mature market lifecycle; roles are primarily sales and account management focused rather than innovation-driven. Professionals should expect cost-minimization strategies, generic competition defense, and potential role elimination as the product enters post-LOE phase.